Tag Archive for: Precision Oncology

Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion

/in

Financing led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and others Akribion is pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion Experienced team with a background in biotechnology and company building led by co-CEO’s Michael Krohn and Lukas Linnig Paul Scholz, the principal inventor of G-dase E technology, joins […]

Read more

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

/in

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investors Oncode Oncology Bridge Fund, Swanbridge and BOM Flindr discovers and develops precision oncology therapeutics with the potential to eradicate tumors in specific patient populations Lead asset is a […]

Read more

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

/in

PhenoScope can cut drug development time and costs significantly, while delivering safer & more effective therapy for cancer patients It can provide more precise patient dosing to reduce side effects, increase efficiency and reduce wastage CHICAGO, IL & PALO ALTO, CA – 3 April 2024 – SimBioSys, a leading innovator in precision oncology, and General […]

Read more

New Horizons for Bio Innovation: Top takeaways from OnHelix 2023

/in

One Nucleus’ On Helix Conference 2023, provided insight into the current climate for Biotech companies, including the international outlook, and what to expect in the future.   The past few years have been tough for the international Biotech market, with funding, Brexit, new regulations, trade agreements and supply chain issues. Additionally, valuations have fallen and consequently […]

Read more